Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Kronos Bio, Inc.
  6. Summary
    KRON   US50107A1043

KRONOS BIO, INC.

(KRON)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
16.49(c) 16.24(c) 16.51(c) 16.88(c) 16.18 Last
117 475 104 419 76 551 94 390 58 862 Volume
-1.73% -1.52% +1.66% +2.24% -4.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -142 M - -
Net cash position 2021 164 M - -
P/E ratio 2021 -6,30x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -162 M - -
Net cash position 2022 292 M - -
P/E ratio 2022 -5,64x
Yield 2022 -
Capitalization 950 M 950 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 90
Free-Float 83,0%
More Financials
Company
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered,... 
More about the company
Ratings of Kronos Bio, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about KRONOS BIO, INC.
09/30KRONOS BIO : to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC..
GL
09/30Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MY..
CI
09/14KRONOS BIO : Appoints Marni Kottle as Senior Vice President of Corporate Communications an..
AQ
09/14Kronos Bio, Inc. Appoints Marni Kottle as Senior Vice President of Corporate Communicat..
CI
09/09INSIDER SELL : Kronos Bio
MT
09/07KRONOS BIO : Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conf..
AQ
08/12KRONOS BIO : Announced FDA clearance of Investigational New Drug application (IND) for lan..
PU
08/12KRONOS BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
08/12KRONOS BIO, INC. : Results of Operations and Financial Condition, Financial Statements and..
AQ
08/12Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
GL
08/12Kronos Bio, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended..
CI
07/27KRONOS BIO : to Proceed With Clinical Trials of Combination Therapy for Acute Myeloid Leuk..
MT
07/27KRONOS BIO : Announces FDA Clearance of Investigational New Drug Application for Lanraplen..
AQ
07/27Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraple..
CI
06/25KRONOS BIO : Financial Statements and Exhibits (form 8-K/A)
AQ
More news
News in other languages on KRONOS BIO, INC.
09/09VENTE D'INITIÉS : Kronos Bio
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Chart KRONOS BIO, INC.
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 16,88 $
Average target price 42,25 $
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-43.49%950
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233